EGFR and non-small cell lung carcinoma: The study highlighted the broad applicability of Ivonescimab across multiple therapy lines, including first-line treatment for advanced NSCLC without driver mutations and treatment in patients with EGFR mutations or prior PD-1/L1 inhibitor failures.